missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human PI4KB (aa 517-660) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (100%), Rat (100%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-52271 (PA5-52271. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
PI4KB and PI4KA are the two human type III PI4 kinases, which share sequence similarly with PI3 kinases and phosphorylate the 4 position of phosphotidyl inositol. Transporter for alanine, serine, cysteine, and threonine. Exhibits sodium dependence. Target protein phosphorylates phosphatidylinositol (PtdIns) at the D4 position of the inositol ring; may play a role in neuronal differentiation and maturation.
Specifications
Specifications
| Accession Number | Q9UBF8 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 5298 |
| Name | Human PI4KB (aa 517-660) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | catalytic phosphatidylinositol 4-kinase beta; ESTM41; lipid kinase; DrPI4K III beta; NPIK; phosphatidylinositol 4-kinase; phosphatidylinositol 4-kinase beta; phosphatidylinositol 4-kinase III beta; phosphatidylinositol 4-kinase, catalytic, beta; phosphatidylinositol 4-kinase, catalytic, beta polypeptide; phosphatidylinositol 4-kinase, wortmannin-sensitive; PI4K92; PI4KB; PI4Kbeta; PI4K-beta; PI4KIII; PI4KIIIBETA; PI4KIII-beta; Pik4cb; PtdIns 4-kinase beta; type III phosphatidylinositol 4-kinase beta; zgc:152715 |
| Common Name | PI4KB |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction